Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-04-21 Annual Report
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
2023年年度报告摘要
Annual Report Classification · 95% confidence The document is titled '年度报告摘要' which translates to 'Annual Report Summary' and contains detailed financial data, business descriptions, shareholder information, and management assurances. It includes audited financial figures and mentions an unqualified audit opinion from an accounting firm. The content covers the company's business overview, financial performance, shareholding structure, and other key annual report elements. The document length is 6851 characters, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, this document is the actual Annual Report (10-K equivalent) rather than a mere announcement or summary notice. FY 2023
2024-04-21 Chinese
第六届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 23rd meeting of the 6th Board of Directors of Beijing Xinghao Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements published separately on the Beijing Stock Exchange information disclosure platform. The document does not contain the full reports themselves but rather summarizes and approves them, indicating that these reports are available elsewhere. This type of document is a Board/Management Information announcement, as it relates to board meeting decisions and management reports, not the reports themselves. Therefore, the correct classification is MANG (Board/Management Information). The document length (7220 characters) and content confirm it is not a brief report publication announcement or a full annual report but a board meeting resolution announcement.
2024-04-21 Chinese
董事会关于独立董事独立性情况的专项意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the board of directors of Beijing Xinghao Pharmaceutical Co., Ltd. regarding the independence of its independent directors. It references regulatory guidelines and rules related to independent directors and confirms that the current independent directors meet the independence criteria. The document is a specialized opinion on director independence rather than a full report or financial statement. It does not contain financial data, earnings, or management discussion, nor is it a notice of voting results or a proxy statement. It is a regulatory announcement related to governance but does not detail governance structures or compensation. Therefore, it fits best under Regulatory Filings (RNS) as a compliance-related announcement that does not fit other specific categories.
2024-04-21 Chinese
独立董事2023年度述职报告（杜守颖已离职）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Work Report" and contains detailed descriptions of the independent director's duties, attendance at board meetings, opinions on various company matters, and communication with auditors. It is a report on the independent director's activities and opinions during the year 2023. The document is 3311 characters long, which is relatively short but contains substantive content about board and management activities rather than just an announcement or certification. It is not a full annual report, audit report, or earnings release, but rather a management/board-related report focusing on the independent director's role and activities. Therefore, the most appropriate classification is "Board/Management Information (MANG)" as it relates to board member activities and changes (including resignation).
2024-04-21 Chinese
拟续聘2024年度会计师事务所公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (Beijing Dahua International Accounting Firm) for the 2024 audit services of Beijing Xinghao Pharmaceutical Co., Ltd. It details the accounting firm's qualifications, past audit fees, and the approval process by the board and audit committee. There are no actual financial statements or audit results presented, nor is this a full audit report or annual report. The document is relatively short (2679 characters) and serves as a formal announcement of the intention to reappoint the auditor, pending shareholder approval. Therefore, it is not an Audit Report (AR) itself but an announcement related to audit services. Given the nature and length, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about auditor appointment.
2024-04-21 Chinese
关于召开2023年年度股东大会通知公告（提供网络投票）
AGM Information Classification · 95% confidence The document is a notice announcing the convening of the 2023 Annual General Meeting (AGM) of Beijing Xinghao Pharmaceutical Co., Ltd. It details the meeting date, voting methods, agenda items to be discussed, and references to other related reports and announcements that have been or will be disclosed elsewhere. The document does not contain the actual annual report, audit report, or financial statements but rather serves as an official notification for shareholders about the AGM and the matters to be voted on. The document length is 4032 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2024-04-21 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.